2
|
Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 2008; 12:94-9. [DOI: 10.1038/pcan.2008.10] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
4
|
Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C, Vana F, Lamanna G, Tampellini M, Porpiglia F, Angeli A, Scarpa RM, Dogliotti L. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005; 93:633-8. [PMID: 16222309 PMCID: PMC2361623 DOI: 10.1038/sj.bjc.6602767] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Factors predictive of skeletal-related events (SREs) in bone metastatic prostate cancer patients with hormone-refractory disease were investigated. We evaluated the frequency of SREs in 200 hormone-refractory patients consecutively observed at our Institution and followed until death or the last follow-up. Baseline parameters were evaluated in univariate and multivariate analysis as potential predictive factors of SREs. Skeletal-related events were observed in 86 patients (43.0%), 10 of which (5.0%) occurred before the onset of hormone-refractory disease. In univariate analysis, patient performance status (P=0.002), disease extent (DE) in bone (P=0.0001), bone pain (P=0.0001), serum alkaline phosphatase (P=0.0001) and urinary N-telopeptide of type one collagen (P=0.0001) directly correlated with a greater risk to develop SREs, whereas Gleason score at diagnosis, serum PSA, Hb, serum albumin, serum calcium, types of bone lesions and duration of androgen deprivation therapy did not. Both DE in bone (hazard ratio (HR): 1.16, 95% confidence interval (CI): 1.07-1.25, P=0.000) and pain score (HR: 1.13, 95% CI: 1.06-1.20, P=0.000) were independent variables predicting for the onset of SREs in multivariate analysis. In patients with heavy tumour load in bone and great bone pain, the percentage of SREs was almost twice as high as (26 vs 52%, P<0.02) and occurred significantly earlier (P=0.000) than SREs in patients with limited DE in bone and low pain. Bone pain and DE in bone independently predict the occurrence of SREs in bone metastatic prostate cancer patients with hormone-refractory disease. These findings could help physicians in tailoring the skeletal follow-up most appropriate to individual patients and may prove useful for stratifying patients enrolled in bisphosphonate clinical trials.
Collapse
Affiliation(s)
- A Berruti
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - M Tucci
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - A Mosca
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - R Tarabuzzi
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - G Gorzegno
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - C Terrone
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - F Vana
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - G Lamanna
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - M Tampellini
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - F Porpiglia
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - A Angeli
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - R M Scarpa
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - L Dogliotti
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy. E-mail:
| |
Collapse
|
5
|
Tucci M, Berruti A, Mosca A, Vana F, La Manna G, Russo L, Poggio M, Bitossi R, Gorzegno G, Tampellini M, Saini A. Predictive factors for skeletal complications in prostate cancer patients with hormone refractory disease. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - F. Vana
- ASO S. Luigi, Orbassano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005; 12:383-92. [PMID: 15947110 DOI: 10.1677/erc.1.00945] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2-4, N0-1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus tamoxifen (EPI-TAM). Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI-TAM arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)-negative (ER-) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI and EPI-TAM treatments resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI-TAM arm was greater than in the EPI arm, leading to a lower Ki67 expression at post-operative residual histology (P=0.0041). The addition of tamoxifen to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER- status were both associated with a greater chance of obtaining a pathological complete response at residual histology.
Collapse
Affiliation(s)
- A Bottini
- Breast Unit and Anatomia Patologica Azienda Ospedaliera Istituti Ospitalieri, Cremona, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mosca A, Berruti A, Tucci M, Vana F, Bitossi R, Cracco C, Torta M, Poggio M, Scarpa RM, Dogliotti L. Prognostic role of plasma chromogranin A levels in prostate cancer patients with hormone refractory disease. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Mosca
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - A. Berruti
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - M. Tucci
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - F. Vana
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - R. Bitossi
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - C. Cracco
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - M. Torta
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - M. Poggio
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - R. M. Scarpa
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| | - L. Dogliotti
- Medical Oncology University of Torino at San Luigi Hospital, Orbassano, Italy; Urology University of Torino at San Luigi Hospital, Orbassano, Italy
| |
Collapse
|
8
|
Tucci M, Berruti A, Mosca A, La Manna G, Vana F, Terrone C, Tampellini M, Tarabuzzi R, Gorzegno G, Dogliotti L. The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Tucci
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - A. Berruti
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - A. Mosca
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - G. La Manna
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - F. Vana
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - C. Terrone
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - M. Tampellini
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - R. Tarabuzzi
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - G. Gorzegno
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - L. Dogliotti
- University of Torino at San Luigi Hospital, Orbassano, Italy
| |
Collapse
|